Pfizer Corporation

Feng C Bi

Seiji Nukui

Ru Zhou

Hao Bai

Simon Bailey

Dilip Ramakant Bhumralkar

Anthony Lai Ling

Mingying He

Jihong Lou

Fengli Guo

Paul Stuart Humphries

David Andrew Griffith

Angel Guzman-Perez

Daniel Patrick Walker

Mary Theresa Didiuk

Kevin K Liu

The present invention relates to a compound of formula (I):  or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is (4-12)-membered heterocyclyl; Ring B is a fused benzene ring selected from the group consisting of:  Ring A, ring B, ring C, R, R, R, R, R, L, n, t, w, and z are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of glucokinase, the method comprising administering to a mammal an effective amount of a compound of formula (I).

Fused phenyl amido heterocyclic compounds

The present invention is directed to novel pyrido[4,3-d]pyrimidin-4(3H)-one derivatives and pharmaceutically acceptable salts thereof of structural formula I wherein the variables R, R, R, Rand Rare as described herein. Also provided are pharmaceutical compositions comprising the compounds of formula I as well as methods of treatment employing compounds of formula I to treat a disease or disorder characterized by abnormal bone or mineral homeostasis such as hypoparathyroidism, osteoporosis, osteopenia, periodontal disease, Paget's disease, bone fracture, osteoarthritis, rheumatoid arthritis, and humoral hypercalcemia of malignancy.

[object Object]

Growing community of inventors

La Jolla, CA, United States of America

Feng C Bi